In the current study, MaR1 treatment significantly restricted inflammation via downregulating the expressions of TNF-α, IL-6, IL-1β, and MCP-1 in LPS-stimulated AKI kidneys and TCMK-1 cells. The gene discussed is TNF; the disease is acute kidney injury.